U.S. Stock Market Midday Update: FDA Lifts Clinical Hold but Can't Save the Market, GH Research Shares Drop 12.03%

U.S. Stock Market Midday Update GH Research fell 12.03%. Based on recent key news: On January 5, GH Research announced that the FDA lifted the clinical hold on its GH001 drug, allowing for subject recruitment in the United States. This development propelled the company's development plans in major jurisdictions, with the stock price rising 42% in pre-market trading. On January 5, GH Research showed significant efficacy in a Phase 2b trial, with patients experiencing a reduction of 15.5 points in Montgomery-Asberg Depression Rating Scale within 8 days. Despite a roughly 28% increase in stock price over the past year, it has not fully recovered the gains made since its listing in 2021. On January 5, GH Research's stock price rose 34.52% during the press conference, reflecting the market's positive response to its clinical trial results. The biotechnology industry is experiencing increased volatility, and risks should be monitored. Top Stocks by Trading Volume in the Industry Eli Lilly rose 1.47%, with increased trading volume. Based on recent key news: On January 7, Eli Lilly reached a research and development agreement with Nimbus, driving the stock price up. Eli Lilly will pay a $55 million upfront fee and may receive up to $1.3 billion in milestone payments. Source: MT Newswires On January 6, Eli Lilly significantly reduced the price of Mounjaro in China in response to market competition pressures. The monthly fee for the lowest dose was lowered to 599 RMB, nearly 70% lower than last year. Source: Wall Street Insight On January 5, LEERINK PARTNERS raised Eli Lilly's target price to $1,234, reflecting market confidence in its future growth. Source: Zhitong Finance. The weight loss drug market is highly competitive, with significant policy impacts. Novo Nordisk rose 1.79%. Based on recent key news: On January 4, the Supreme People's Court of China made a favorable ruling on the patent for semaglutide compounds, enhancing Novo Nordisk's confidence in its development in China, which drove the stock price up. Source: Zhitong Finance On January 5, Novo Nordisk launched an oral version of Wegovy in the United States, expanding distribution channels, with a positive market response and rising stock price. Source: Zhitong Finance On January 5, Novo Nordisk's head of public affairs in the U.S. resigned, and the company is undergoing a business reorganization, with the market taking a wait-and-see attitude towards its future development. Source: Reuters. The weight loss drug market is highly competitive, with policy support for innovation. Alumis rose over 90%. Based on recent key news: On January 6, Alumis announced that its drug envudeucitinib achieved significant results in a Phase 3 trial for the treatment of moderate to severe plaque psoriasis. The drug met all primary and secondary endpoints in the trial, with 65% of patients achieving PASI 90 by week 24, and over 40% achieving PASI 100, with good safety. This result propelled the stock price up over 110% Source: Zhitong Finance On January 6, Alumis plans to submit a new drug application to the FDA in the second half of 2026, seeking approval for envudeucitinib in the United States. This move further enhances investors' confidence in its market prospects. Source: Wall Street Insights On January 6, Alumis' stock price reached a 52-week high, reflecting the market's optimistic expectations for its potential in the treatment of psoriasis. Source: Benzinga The biotechnology industry has recently performed strongly, with significant capital inflows. Top stocks by industry market capitalization Johnson & Johnson rose 0.44%, with increased trading volume. Based on recent key news: On January 6, Johnson & Johnson announced that its drug nipocalimab for the treatment of systemic lupus erythematosus (SLE) achieved positive results in the Phase 2b JASMINE study. The study met its primary endpoint, significantly improving patients' SLE response index (SRI-4) composite response. This news drove the stock price up. On January 6, Johnson & Johnson submitted an application to the European Medicines Agency for the combined use of TECVAYLI® and DARZALEX® for the treatment of relapsed/refractory multiple myeloma patients. This move demonstrates the company's ongoing investment in innovative drug development, enhancing market confidence. On January 5, Johnson & Johnson plans to achieve a 5% to 7% annual compound growth rate through the launch of new medical technology products and innovative drugs. The company also plans to supplement its organic growth through strategic acquisitions, a growth strategy viewed positively by the market. The pharmaceutical industry is active in innovative drug research and development, with increased market confidence